VIGAMOX Drug Patent Profile

When do Vigamox patents expire, and when can generic versions of Vigamox launch?

Vigamox is a drug marketed by Harrow Eye and is included in one NDA.

The generic ingredient in VIGAMOX is moxifloxacin hydrochloride. There are eighteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the moxifloxacin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vigamox

A generic version of VIGAMOX was approved as moxifloxacin hydrochloride by TEVA PHARMS USA on February 18^th, 2014.

Summary for VIGAMOX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	105
Clinical Trials:	34
Patent Applications:	2,264
Drug Prices:	Drug price information for VIGAMOX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIGAMOX
What excipients (inactive ingredients) are in VIGAMOX?	VIGAMOX excipients list
DailyMed Link:	VIGAMOX at DailyMed

See drug prices for VIGAMOX

See drug sales revenues for VIGAMOX

Recent Clinical Trials for VIGAMOX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tanta University	EARLY_PHASE1
Kafrelsheikh University	Phase 4
Benha University	Phase 1

See all VIGAMOX clinical trials

Pharmacology for VIGAMOX

Drug Class

Fluoroquinolone Antibacterial

Paragraph IV (Patent) Challenges for VIGAMOX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIGAMOX	Ophthalmic Solution/Drops	moxifloxacin hydrochloride	0.5%	021598	1	2005-12-22

US Patents and Regulatory Information for VIGAMOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harrow Eye	VIGAMOX	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	021598-001	Apr 15, 2003	AT1	RX	Yes	Yes

International Patents for VIGAMOX

See the table below for patents covering VIGAMOX around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	135354
Austria	292127
Australia	1028392

Supplementary Protection Certificates for VIGAMOX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0350733	300111	Netherlands
0350733	SPC/GB03/034	United Kingdom		PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313
0350733	2001C/030	Belgium		PRODUCT NAME: MOXIFLOXACINE CHLORHYDRATE (CORRESPONDANT A MOXIFLOXACINE); NATL. REGISTRATION NO/DATE: 187 IS 328 F 3 20010507; FIRST REGISTRATION: DE 45263.00.00 19990621

Last updated: July 13, 2026

Vigamox (moxifloxacin ophthalmic) Market Dynamics and Financial Trajectory: Sales Trends, Generic/Biosimilar Risk, and Profit Drivers

Vigamox (moxifloxacin hydrochloride ophthalmic solution) is a branded fluoroquinolone eye drop with U.S. revenue concentrated in prescription channels and a protection tail driven by formulation, use, and process patents plus ongoing brand-competitor pricing pressure. The long-run financial trajectory is shaped by (1) generic erosion risk after patent and exclusivity expiry, (2) competitive intensity from other fluoroquinolone drops and combination products, and (3) payer and channel conversion into lower-cost equivalents.

What is Vigamox’s commercial profile and where does demand come from?

Vigamox is an ophthalmic antibiotic used primarily for bacterial conjunctivitis and related ocular bacterial infections. Commercial demand is driven by:

• Prescriber selection within the fluoroquinolone class, especially where rapid empiric coverage is favored.
• Setting-level prescribing patterns (retail chain formularies, integrated delivery networks, urgent care and ophthalmology clinics).
• Seasonality and regional incidence of bacterial conjunctivitis, with demand smoothing around peak seasonal periods.

What patient indications drive prescribing and script volume?

• Acute bacterial conjunctivitis and related bacterial ocular infections.
• Use patterns aligned with ophthalmology and primary care referral flows.

How does channel structure affect brand pricing power?

• Retail pharmacy reimbursement and formulary placement dominate short-cycle brand performance.
• Hospital or clinic stocking is smaller than retail for typical ophthalmic antibiotics, but can matter in outbreaks or seasonal surges.

How do competitive dynamics in topical fluoroquinolone ophthalmics affect Vigamox sales?

The competitive set for Vigamox is the broader topical fluoroquinolone market, where efficacy and dosing convenience drive switching. Key dynamics:

• Price compression when generics for moxifloxacin ophthalmics enter and when alternative fluoroquinolones price-match.
• Clinical differentiation based on perceived spectrum, dosing frequency, and tolerability, which can persist even when acquisition costs fall.
• Formulary routing that favors the lowest net cost once at least one therapeutically acceptable generic is available.

Which rival products most pressure Vigamox pricing?

• Other fluoroquinolone eye drops (class competition).
• Combination antibiotic-steroid ophthalmics in post-procedural settings (selective use, not direct replacement).
• Lower-cost generics of competing fluoroquinolones that can trade off with formulary lock.

What pricing levers determine brand survival when generics exist?

• Rebates and payer contracting to preserve formulary position.
• Supply continuity and package presentation (multi-pack strategies, strength, and bottle size).
• Detail-driven prescribing in ophthalmology, where switching can be slower than in retail.

How many years of brand protection does Vigamox have in the U.S., and when does exclusivity end?

A complete, accurate U.S. exclusivity timeline requires Orange Book patent and exclusivity entries for Vigamox’s specific NDA and product strength (including patent numbers and expiry dates). Without that record, providing exact expiry years would be speculative.

What does the Orange Book status imply for generic entry risk?

Generic entry risk is tied to:

• Whether relevant patents are listed for Vigamox’s NDA.
• Whether those patents cover formulations, manufacturing, or methods of use.
• Whether any unexpired exclusivities (non-patent exclusivities) apply to the product.

Without the Orange Book listing set, the probability and timing of Paragraph IV filings cannot be stated precisely.

When could generic moxifloxacin eye drops launch, and what scenarios affect market share loss?

Generic entry scenarios typically follow one of two patterns in ophthalmics:

• Immediate share shift after launch: strong formulary switching, rapid conversion in retail channels, and pharmacist-led substitution.
• Gradual erosion: brand retains share due to ophthalmology loyalty, patient-specific tolerability, or delayed contract renegotiation.

What determines speed of share loss for ophthalmic generics?

• Pharmacy benefit manager (PBM) formulary updates.
• Therapeutic interchange rules in each state.
• Competitive contracting and rebate restructuring after generic launch.

What revenue exposure persists after generic entry?

• Brand can retain incremental share if generic penetration is incomplete or if branded contracting offsets price differences.
• Higher-acuity ophthalmology practices may maintain brand choice if clinical workflows and outcomes are favored.

What financial trajectory should investors expect for Vigamox revenue?

A defensible financial trajectory for Vigamox depends on documented sales history and segment reporting by the current marketing authorization holder, including:

• Annual U.S. net sales and trend rates.
• Gross-to-net dynamics (rebates, discounts, chargebacks).
• Script volumes and average selling price (ASP) decline after generic milestones.
• Inventory and supply disruptions, if any.

This request requires sales data inputs not provided here. Producing a numeric trajectory would require those figures to be cited.

How do gross-to-net and rebate structures typically change as patent protection erodes?

As generic pressure grows, brand-to-generic price differentials force:

• Higher rebate pressure to defend formulary placement.
• Increased promotional spend for patient and prescriber retention.
• Mix shift to higher-margin presentations or contract-driven volume.

For ophthalmic products, the key financial swing factor is often ASP decline rather than pure volume loss, since volume can remain stable while revenue per script falls.

What patent litigation and Paragraph IV challenges affect Vigamox market dynamics?

Patent litigation, including Paragraph IV certifications and settlement terms, typically determines:

• Launch delay windows.
• At-risk launch timing.
• Authorized generic arrangements and “carve-out” settlement structures.

A complete analysis requires the Vigamox patent set and any litigation dockets tied to the specific NDA product. No case docket details were provided.

What settlement outcomes are most material for Vigamox financials?

For ophthalmics, settlement outcomes that most affect financial trajectory are:

• “Pay-for-delay” style commitments that delay generic launch.
• Agreements allowing earlier launch of certain strengths, package sizes, or labeling.
• Authorized generic exposure that accelerates erosion while reducing price volatility.

Without settlement documents and dates, no specific scenario can be stated.

How does manufacturing/IP strategy shape barriers to entry for generic moxifloxacin drops?

Manufacturing and IP barriers that can slow generic adoption include:

• Process patents tied to specific manufacturing steps or impurity controls.
• Formulation patents covering particle characteristics, preservatives, pH stabilization, or container/closure compatibility.
• Analytical method IP that complicates biosimilar-like equivalency work (less typical for small molecules, but method and process patents can still matter).

A reliable barrier map requires the listed patent claims for Vigamox and any known generic challengers.

How does Vigamox compare with other ophthalmic fluoroquinolones on market positioning?

High-level comparison framework:

• Dosing frequency and ease of use influence adherence and prescriber preference.
• Perceived spectrum and clinical pathway fit drives first-line selection in bacterial conjunctivitis.
• Brand contracting determines net pricing and formulary placement outcomes more than labeling alone.

A product-by-product financial comparison requires current market share or sales data by competitor, and is not possible with inputs not provided.

Key takeaways

• Vigamox’s market dynamics are dominated by topical fluoroquinolone competition and the pace of generic adoption once relevant patent and exclusivity barriers clear.
• Financial trajectory typically follows an ASP decline and gross-to-net pressure curve post-launch, even when script volume remains relatively steady.
• A precise exclusivity, generic entry timing, and litigation-driven timeline requires the specific Orange Book listing set and associated patent expiry dates and litigation records for Vigamox’s NDA product.

FAQs

1) Is Vigamox still protected in the U.S., and what patents are the main barriers?

A precise answer requires the Orange Book patent and exclusivity listings tied to the exact Vigamox NDA product/strength.

2) What generic moxifloxacin ophthalmic products compete most directly with Vigamox?

The closest competitors are other moxifloxacin ophthalmic generics and alternative fluoroquinolone eye drops with overlapping indications.

3) How fast do ophthalmic generics usually erode branded revenue after launch?

Erosion speed depends on PBM formulary updates and rebate restructuring, with many ophthalmics seeing rapid channel switching once substitution is permitted.

4) Does Vigamox have pricing pressure from fluoroquinolone combination products?

Combination antibiotic-steroid ophthalmics can pressure selection in specific post-procedural or inflammatory contexts, but they do not fully replace fluoroquinolone-only workflows.

5) What financial metrics best track Vigamox performance quarter to quarter?

Net sales growth, ASP trends, gross-to-net changes (rebates/chargebacks), and prescription volume trends are the core indicators.

References

1. FDA Orange Book: Data for Vigamox (moxifloxacin hydrochloride ophthalmic solution). U.S. Food and Drug Administration.
2. FDA Drug Databases: Drugs@FDA for Vigamox (moxifloxacin hydrochloride ophthalmic solution). U.S. Food and Drug Administration.

DrugChatter Q&A for VIGAMOX

Vigamox eye drops substitute?
Price of vigamox eye drops?
Vigamox price philippines?
Vigamox 0 5 eye drops price?